Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biostate SP is a high-purity, plasma-derived concentrate of human von Willebrand factor (VWF) and coagulation factor VIII (FVIII), developed by CSL Behring. It is a specific formulation variant of the established product Biostate, characterized by a VWF:FVIII ratio of approximately 2.4:1 and the presence of high-molecular-weight VWF multimers. The 'SP' designation refers to a formulation evaluated in a Phase II clinical trial (NCT00879541) to assess its efficacy, safety, and pharmacokinetics in patients with haemophilia A. The drug acts as a replacement therapy, restoring the coagulation cascade by supplementing deficient levels of FVIII and VWF, thereby facilitating normal blood clotting in patients with haemophilia A or von Willebrand disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biostate SP.